---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003207"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:39:47.896180+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics reports Q1 net loss of $2.8M; cash burn down; clinical progress in iNKT platform

## Summary
- Net loss of $2.8M ($0.70/sh) vs $3.8M ($1.10/sh) YoY; cash used in ops down to $1.3M from $2.5M.
- Cash balance of $3.2M at March 31, 2025; company pursuing near-term capital transactions to bolster liquidity.
- Phase 2 gastric trial (NCT06251973) enrolling; new data shows agenT-797 activity in PD-1-resistant gastroesophageal cancers.
- Complete remission in metastatic testicular cancer after single agenT-797 infusion without lymphodepletion or toxicity.
- Selected for probable NIAID funding for GvHD program; strategic discussions underway across oncology and immunology.

## SEC filing metadata
- accession: 0001171843-25-003207
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000117184325003207/0001171843-25-003207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000117184325003207/f8k_051525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003207
- JSON: https://secwatch.observer/filing/0001171843-25-003207.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.